No Data
No Data
Beijing Centergate Technologies (000931.SZ): Currently, its subsidiary Taihe Retirement owns more than ten retirement projects.
On August 8th, GeLongHui reported that Beijing Centergate Technologies (Stock Code: 000931.SZ) stated in an investor relations event that its subsidiary, Beijing Taihe Retirement Service Industry Development Co., Ltd. (referred to as: Taihe Retirement), currently has more than ten retirement projects and adopts a chain operation model. In terms of brand influence, personnel services, equipment, elderly products, and food procurement, the costs are relatively advantageous compared to single retirement institutions. In recent years, the company has paid particular attention to standardized construction. Several of its retirement projects have won the title "Three-Star Retirement Institution," and its Nalan Garden project was even awarded the title of "Four-Star Retirement Institution," to a certain extent.
Beijing Centergate Technologies (000931.SZ): The consistency evaluation application of Duoduo Pharmaceutical tramadol hydrochloride injection has been accepted.
Beijing Centergate Technologies (000931.SZ) announced that its subsidiary company Duoduoyao Pharmaceutical Co., Ltd. (referred to as Duoduoyao) ...
Beijing Centergate Technologies: 2024 Interim Performance Forecast
Zhongguancun (000931.SZ): Subsidiary company Duoduo Pharmaceutical Ambroxol Hydrochloride Injection received the “Notice of Acceptance” from the State Drug Administration
Gelonghui, April 29丨Zhongguancun (000931.SZ) announced that Duoduo Pharmaceutical Co., Ltd. (hereinafter: Duoduo Pharmaceutical), a subsidiary of the company, recently received the “Notice of Acceptance” of the registration application for the chemical generic drug ambroxol hydrochloride injection issued by the China Drug Administration (hereinafter referred to as the State Drug Administration).
Zhongguancun (000931.SZ): Net profit of 116.311 million yuan in the first quarter increased 22.88% year-on-year
Gelonghui, April 26 | Zhongguancun (000931.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 606 million yuan, up 3.06% year on year; net profit attributable to shareholders of listed companies was 116.311 million yuan, up 22.88% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 6.6067 million yuan, down 1.66% year on year; basic earnings per share were 0.0154 yuan.
Zhongguancun (000931.SZ): Subsidiary company Beijing Huasubanbazol API approved for listing
Gelonghui, April 22丨Zhongguancun (000931.SZ) announced that Beijing Huasu Pharmaceutical Co., Ltd. (hereinafter: Beijing Huasu), a subsidiary of Beijing Zhongguancun Science and Technology Development (Holdings) Co., Ltd. (hereinafter referred to as the Company), recently passed the technical review by the Drug Evaluation Center of the State Drug Administration (CDE) and obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the China Drug Administration (hereinafter referred to as the State Drug Administration). Bifonazole raw materials are indicated for antifungal infections. Bifonazol (Bifonaz
No Data